Facteurs de risque de la maladie d’Alzheimer et des maladies apparentées : approche parcours de vie

Association As, 2017, 2017 Alzheimer's disease facts and figures, Alzheimers Dement, 13, 325 Haut Conseil de la santé publique, 2017 Hardy, 1992, Alzheimer's disease: the amyloid cascade hypothesis, Science, 256, 184, 10.1126/science.1566067 Glenner, 1984, Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein, Biochem Biophys Res Commun, 120, 885, 10.1016/S0006-291X(84)80190-4 Hardy, 2002, The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics, Science, 297, 353, 10.1126/science.1072994 Knopman, 2019, Lowering of amyloid-beta by beta-secretase inhibitors - some informative failures, N Engl J Med, 380, 1476, 10.1056/NEJMe1903193 Egan, 2018, Randomized trial of verubecestat for mild-to-moderate Alzheimer's disease, N Engl J Med, 378, 1691, 10.1056/NEJMoa1706441 Bennett, 2006, Neuropathology of older persons without cognitive impairment from two community-based studies, Neurology, 66, 1837, 10.1212/01.wnl.0000219668.47116.e6 Knopman, 2003, Neuropathology of cognitively normal elderly, J Neuropathol Exp Neurol, 62, 1087, 10.1093/jnen/62.11.1087 Katzman, 1988, Clinical, pathological, and neurochemical changes in dementia: a subgroup with preserved mental status and numerous neocortical plaques, Ann Neurol, 23, 138, 10.1002/ana.410230206 Savva, 2009, Age, neuropathology, and dementia, N Engl J Med, 360, 2302, 10.1056/NEJMoa0806142 Jack, 2013, Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers, Lancet Neurol, 12, 207, 10.1016/S1474-4422(12)70291-0 Schneider, 2007, Mixed brain pathologies account for most dementia cases in community-dwelling older persons, Neurology, 69, 2197, 10.1212/01.wnl.0000271090.28148.24 Winblad, 2016, Defeating Alzheimer's disease and other dementias: a priority for European science and society, Lancet Neurol, 15, 455, 10.1016/S1474-4422(16)00062-4 Whalley, 2006, A life-course approach to the aetiology of late-onset dementias, Lancet Neurol, 5, 87, 10.1016/S1474-4422(05)70286-6 Singh-Manoux, 2018, Le concept de santé cognitive : implications pour la recherche sur la démence, Quest Sante Publ, 35 Kivipelto, 2006, Risk score for the prediction of dementia risk in 20 years among middle aged people: a longitudinal, population-based study, Lancet Neurol, 5, 735, 10.1016/S1474-4422(06)70537-3 Barnes, 2011, The projected effect of risk factor reduction on Alzheimer's disease prevalence, Lancet Neurol, 10, 819, 10.1016/S1474-4422(11)70072-2 Norton, 2014, Potential for primary prevention of Alzheimer's disease: an analysis of population-based data, Lancet Neurol, 13, 788, 10.1016/S1474-4422(14)70136-X Livingston, 2017, Dementia prevention, intervention, and care, Lancet, 390, 2673, 10.1016/S0140-6736(17)31363-6 Pankratz, 2015, Predicting the risk of mild cognitive impairment in the Mayo Clinic Study of Aging, Neurology, 84, 1433, 10.1212/WNL.0000000000001437 Kivimaki, 2018, Prevention of dementia by targeting risk factors, Lancet, 391, 1574, 10.1016/S0140-6736(18)30578-6 Brayne, 2017, Dementia and aging populations – a global priority for contextualized research and health policy, PLoS Med, 14, e1002275, 10.1371/journal.pmed.1002275 Lamb, 2018, Dementia And Physical Activity (DAPA) trial of moderate to high intensity exercise training for people with dementia: randomised controlled trial, BMJ, 361, k1675, 10.1136/bmj.k1675 Brasure, 2018, Physical Activity interventions in preventing cognitive decline and Alzheimer-type dementia: a systematic review, Ann Intern Med, 168, 30, 10.7326/M17-1528 Sabia, 2017, Physical activity, cognitive decline, and risk of dementia: 28 year follow-up of Whitehall II cohort study, BMJ, 357, j2709, 10.1136/bmj.j2709 Hamer, 2009, Physical activity and risk of neurodegenerative disease: a systematic review of prospective evidence, Psychol Med, 39, 3, 10.1017/S0033291708003681 Morgan, 2012, Physical activity in middle-age and dementia in later life: findings from a prospective cohort of men in Caerphilly, South Wales and a meta-analysis, J Alzheimers Dis, 31, 569, 10.3233/JAD-2012-112171 Singh-Manoux, 2017, Trajectories of depressive symptoms before diagnosis of dementia: a 28-year follow-up study, JAMA Psychiatry, 74, 712, 10.1001/jamapsychiatry.2017.0660 Dotson, 2010, Recurrent depressive symptoms and the incidence of dementia and mild cognitive impairment, Neurology, 75, 27, 10.1212/WNL.0b013e3181e62124 Singh-Manoux, 2018, Obesity trajectories over 28 years and risk of dementia: a longitudinal study, Alzheimers Dement, 14, 178, 10.1016/j.jalz.2017.06.2637 Singh-Manoux, 2018, Obesity trajectories and risk of dementia: 28 years of follow-up in the Whitehall II Study, Alzheimers Dement, 14, 178, 10.1016/j.jalz.2017.06.2637 Abell, 2018, Association between systolic blood pressure and dementia in the Whitehall II cohort study: role of age, duration, and threshold used to define hypertension, Eur Heart J, 39, 3119, 10.1093/eurheartj/ehy288 Tuligenga, 2014, Midlife type 2 diabetes and poor glycaemic control as risk factors for cognitive decline in early old age: a post-hoc analysis of the Whitehall II cohort study, Lancet Diabetes Endocrinol, 2, 228, 10.1016/S2213-8587(13)70192-X Singh-Manoux, 2017, Atrial fibrillation as a risk factor for cognitive decline and dementia, Eur Heart J, 38, 2612, 10.1093/eurheartj/ehx208 Kivimaki, 2019, Physical inactivity, cardiometabolic disease, and risk of dementia: an individual-participant meta-analysis, BMJ, 365, l1495, 10.1136/bmj.l1495 Kivimaki, 2018, Body mass index and risk of dementia: Analysis of individual-level data from 1.3 million individuals, Alzheimers Dement, 14, 601, 10.1016/j.jalz.2017.09.016 Wallace, 2019, Investigation of frailty as a moderator of the relationship between neuropathology and dementia in Alzheimer's disease: a cross-sectional analysis of data from the Rush Memory and Aging Project, Lancet Neurol, 18, 177, 10.1016/S1474-4422(18)30371-5 Melis, 2013, The influence of multimorbidity on clinical progression of dementia in a population-based cohort, PLoS One, 8, e84014, 10.1371/journal.pone.0084014 Sweeney, 2018, Blood-brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders, Nat Rev Neurol, 14, 133, 10.1038/nrneurol.2017.188 Brookmeyer, 2018, Estimation of lifetime risks of Alzheimer's disease dementia using biomarkers for preclinical disease, Alzheimers Dement, 14, 981, 10.1016/j.jalz.2018.03.005 O’Bryant, 2019, Blood biomarkers for use in alzheimer disease-moving from “If” to “How?”, JAMA Neurol, 76, 1009, 10.1001/jamaneurol.2019.0845 Hampel, 2018, Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic, Nat Rev Neurol, 14, 639, 10.1038/s41582-018-0079-7 Sun, 2018, Genomic atlas of the human plasma proteome, Nature, 558, 73, 10.1038/s41586-018-0175-2 Emilsson, 2008, Genetics of gene expression and its effect on disease, Nature, 452, 423, 10.1038/nature06758 O’Bryant, 2014, Validation of a serum screen for Alzheimer's disease across assay platforms, species, and tissues, J Alzheimers Dis, 42, 1325, 10.3233/JAD-141041 Hye, 2014, Plasma proteins predict conversion to dementia from prodromal disease, Alzheimers Dement, 10, 10.1016/j.jalz.2014.05.1749 Dey, 2019, Deep undepleted human serum proteome profiling toward biomarker discovery for Alzheimer's disease, Clin Proteomics, 16, 16, 10.1186/s12014-019-9237-1 Cummings, 2018, Alzheimer's disease drug development pipeline: 2018, Alzheimers Dement (N Y), 4, 195, 10.1016/j.trci.2018.03.009 Santos, 2017, A comprehensive map of molecular drug targets, Nat Rev Drug Discov, 16, 19, 10.1038/nrd.2016.230